Kedhi E, Verdoia M, Suryapranata H, et al. - By performing this sub-analysis of the REDUCE trial (a prospective, multicenter, investigator-initiated study), researchers investigated the influence of age on the comparison between a short 3 months vs standard 12 months dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients managed with the COMBO Dual Stent Therapy. In the REDUCE trial, ACS patients receiving percutaneous coronary revascularization with the COMBO drug eluting stent were randomly assigned to either 3 or 12 months of DAPT. Participants were grouped based on age (